Product Name: CDX2 Antibody [CDX2/1690]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlIF: 1-2 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 min at RTThe concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CDX2 antibody to be titered up or down for optimal performance.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Amino acids 150-249 from the human protein were used as the immunogen for this CDX2 antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 541-15-1
Product: L-Carnitine
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CDX2 Antibody: CDX3, CDX-3, CDX3, Homeobox protein CDX-2
Accession NO.:
Protein Ino:
Official Symbol: CDX2
Geneid: 1045
Background: The intestine-specific transcription factors CDX1 and CDX2 are important for directing intestinal development, differentiation, proliferation and maintenance of the intestinal phenotype. CDX2 protein expression has been seen in GI carcinomas. Anti-CDX2 has been useful to establish GI origin of metastatic adenocarcinomas and carcinoids and is especially useful to distinguish metastatic colorectal adenocarcinoma from lung adenocarcinoma. However, mucinous carcinomas of the ovary also express CDX2 protein. It limits the usefulness of this marker in the distinction of metastatic colorectal adenocarcinoma from mucinous carcinoma of the ovary.
PubMed ID:http://aac.asm.org/content/35/9/1925.abstract
